-$0.27 EPS Expected for Adverum Biotechnologies Inc (NASDAQ:ADVM) This Quarter

Share on StockTwits

Analysts predict that Adverum Biotechnologies Inc (NASDAQ:ADVM) will post ($0.27) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have made estimates for Adverum Biotechnologies’ earnings, with the lowest EPS estimate coming in at ($0.30) and the highest estimate coming in at ($0.24). Adverum Biotechnologies posted earnings per share of ($0.26) in the same quarter last year, which would indicate a negative year over year growth rate of 3.8%. The company is scheduled to issue its next quarterly earnings results on Thursday, November 14th.

According to Zacks, analysts expect that Adverum Biotechnologies will report full-year earnings of ($1.02) per share for the current financial year, with EPS estimates ranging from ($1.20) to ($0.95). For the next fiscal year, analysts forecast that the business will report earnings of ($1.13) per share, with EPS estimates ranging from ($1.22) to ($1.08). Zacks’ EPS averages are an average based on a survey of sell-side analysts that cover Adverum Biotechnologies.

Adverum Biotechnologies (NASDAQ:ADVM) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.08. Adverum Biotechnologies had a negative return on equity of 31.21% and a negative net margin of 4,505.40%.

ADVM has been the topic of a number of recent research reports. Zacks Investment Research lowered Adverum Biotechnologies from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 30th. Chardan Capital dropped their target price on Adverum Biotechnologies from $10.00 to $6.00 and set a “neutral” rating on the stock in a report on Friday. Raymond James initiated coverage on Adverum Biotechnologies in a report on Thursday, June 13th. They set a “market perform” rating on the stock. Cowen reaffirmed a “buy” rating on shares of Adverum Biotechnologies in a report on Tuesday, July 9th. Finally, SunTrust Banks decreased their target price on shares of Adverum Biotechnologies from $12.00 to $8.00 and set a “hold” rating for the company in a research note on Friday. Seven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $9.60.

Large investors have recently bought and sold shares of the stock. Bank of Montreal Can bought a new stake in shares of Adverum Biotechnologies during the 2nd quarter valued at about $54,000. SG Americas Securities LLC acquired a new position in shares of Adverum Biotechnologies during the 1st quarter worth $60,000. BNP Paribas Arbitrage SA boosted its holdings in shares of Adverum Biotechnologies by 94.9% during the 1st quarter. BNP Paribas Arbitrage SA now owns 16,504 shares of the biotechnology company’s stock worth $86,000 after buying an additional 8,038 shares during the period. Metropolitan Life Insurance Co NY bought a new stake in shares of Adverum Biotechnologies during the 1st quarter worth $108,000. Finally, Meeder Asset Management Inc. boosted its holdings in shares of Adverum Biotechnologies by 372.1% during the 2nd quarter. Meeder Asset Management Inc. now owns 10,694 shares of the biotechnology company’s stock worth $127,000 after buying an additional 8,429 shares during the period. Institutional investors and hedge funds own 71.78% of the company’s stock.

ADVM traded up $0.04 during trading hours on Monday, reaching $5.82. The company’s stock had a trading volume of 37,990 shares, compared to its average volume of 2,392,147. The company has a debt-to-equity ratio of 0.12, a current ratio of 17.79 and a quick ratio of 17.79. The business’s 50-day moving average is $11.75 and its 200-day moving average is $9.24. Adverum Biotechnologies has a fifty-two week low of $2.62 and a fifty-two week high of $16.38. The stock has a market cap of $384.18 million, a PE ratio of -4.94 and a beta of 2.49.

Adverum Biotechnologies Company Profile

Adverum Biotechnologies, Inc, a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema.

Recommended Story: The primary rules of Elliott Wave theory

Get a free copy of the Zacks research report on Adverum Biotechnologies (ADVM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adverum Biotechnologies (NASDAQ:ADVM)

Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

6 Meridian Cuts Holdings in Cisco Systems, Inc.
6 Meridian Cuts Holdings in Cisco Systems, Inc.
47,795 Shares in Danaher Co.  Acquired by 6 Meridian
47,795 Shares in Danaher Co. Acquired by 6 Meridian
6 Meridian Buys 18,311 Shares of Citigroup Inc
6 Meridian Buys 18,311 Shares of Citigroup Inc
Teladoc Health  to Release Quarterly Earnings on Wednesday
Teladoc Health to Release Quarterly Earnings on Wednesday
Lakeland Financial  Set to Announce Quarterly Earnings on Friday
Lakeland Financial Set to Announce Quarterly Earnings on Friday
6 Meridian Sells 566 Shares of Metlife Inc
6 Meridian Sells 566 Shares of Metlife Inc


 
© 2006-2019 Zolmax.